Inhibition of CD95/CD95L (FAS/FASLG) signaling with APG101 prevents invasion and enhances radiation therapy for glioblastoma
CD95 (Fas/APO-1), a death receptor family member, activity has been linked to tumorigenicity in multiple cancers, including glioblastoma multiforme (GBM). A phase II clinical trial on relapsed glioblastoma patients demonstrated that targeted inhibition of CD95 signaling via the CD95 ligand (CD95L) b...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February 16, 2018
|
| In: |
Molecular cancer research
Year: 2018, Volume: 16, Issue: 5, Pages: 767-776 |
| ISSN: | 1557-3125 |
| DOI: | 10.1158/1541-7786.MCR-17-0563 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1158/1541-7786.MCR-17-0563 Verlag, Volltext: https://mcr.aacrjournals.org/content/16/5/767 
|
| Author Notes: | Jonas Blaes, Carina M. Thomé, Philipp-Niclas Pfenning, Petra Rübmann, Felix Sahm, Antje Wick, Theresa Bunse, Torsten Schmenger, Jaromir Sykora, Andreas von Deimling, Benedikt Wiestler, Christian Merz, Manfred Jugold, Uwe Haberkorn, Amir Abdollahi, Jürgen Debus, Christian Gieffers, Claudia Kunz, Martin Bendszus, Michael Kluge, Michael Platten, Harald Fricke, Wolfgang Wick, and Dieter Lemke |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1676524452 | ||
| 003 | DE-627 | ||
| 005 | 20220816223152.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190911s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1541-7786.MCR-17-0563 |2 doi | |
| 035 | |a (DE-627)1676524452 | ||
| 035 | |a (DE-599)KXP1676524452 | ||
| 035 | |a (OCoLC)1341243274 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Blaes, Jonas |e VerfasserIn |0 (DE-588)1045036463 |0 (DE-627)77354058X |0 (DE-576)39835023X |4 aut | |
| 245 | 1 | 0 | |a Inhibition of CD95/CD95L (FAS/FASLG) signaling with APG101 prevents invasion and enhances radiation therapy for glioblastoma |c Jonas Blaes, Carina M. Thomé, Philipp-Niclas Pfenning, Petra Rübmann, Felix Sahm, Antje Wick, Theresa Bunse, Torsten Schmenger, Jaromir Sykora, Andreas von Deimling, Benedikt Wiestler, Christian Merz, Manfred Jugold, Uwe Haberkorn, Amir Abdollahi, Jürgen Debus, Christian Gieffers, Claudia Kunz, Martin Bendszus, Michael Kluge, Michael Platten, Harald Fricke, Wolfgang Wick, and Dieter Lemke |
| 264 | 1 | |c February 16, 2018 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.09.2019 | ||
| 520 | |a CD95 (Fas/APO-1), a death receptor family member, activity has been linked to tumorigenicity in multiple cancers, including glioblastoma multiforme (GBM). A phase II clinical trial on relapsed glioblastoma patients demonstrated that targeted inhibition of CD95 signaling via the CD95 ligand (CD95L) binding and neutralizing Fc-fusion protein APG101 (asunercept) prolonged patient survival. Although CD95 signaling may be relevant for multiple aspects of tumor growth, the mechanism of action of APG101 in glioblastoma is not clear. APG101 action was examined by in vitro proliferation, apoptosis, and invasion assays with human and murine glioma and human microglial cells, as well as in vivo therapy studies with orthotopic gliomas and clinical data. APG101 inhibits CD95L-mediated invasion of glioma cells. APG101 treatment was effective in glioma-bearing mice, independently of the presence or absence of CD4 and CD8 T lymphocytes, which should be sensitive to CD95L. Combined with radiotherapy, APG101 demonstrated a reduction of tumor growth, fewer tumor satellites, reduced activity of matrix metalloproteinases (MMP) as well as prolonged survival of tumor-bearing mice compared with radiotherapy alone. Inhibiting rather than inducing CD95 activity is a break-of-paradigm therapeutic approach for malignant gliomas. Evidence, both in vitro and in vivo, is provided that CD95L-binding fusion protein treatment enhanced the efficacy of radiotherapy and reduced unwanted proinfiltrative effects by reducing metalloproteinase activity by directly affecting the tumor cells. - Implications: APG101 (asunercept) successfully used in a controlled phase II glioblastoma trial (NCT01071837) acts anti-invasively by inhibiting matrix metalloproteinase signaling, resulting in additive effects together with radiotherapy and helping to further develop a treatment for this devastating disease. Mol Cancer Res; 16(5); 767–76. ©2018 AACR. | ||
| 700 | 1 | |a Sahm, Felix |d 1984- |e VerfasserIn |0 (DE-588)1022852132 |0 (DE-627)717318478 |0 (DE-576)366075020 |4 aut | |
| 700 | 1 | |a Wick, Antje |d 1972- |e VerfasserIn |0 (DE-588)122759869 |0 (DE-627)706032101 |0 (DE-576)293409609 |4 aut | |
| 700 | 1 | |a Deimling, Andreas von |d 1959- |e VerfasserIn |0 (DE-588)103034115X |0 (DE-627)735093946 |0 (DE-576)378138065 |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 700 | 1 | |a Abdollahi, Amir |e VerfasserIn |0 (DE-588)129612715 |0 (DE-627)474757765 |0 (DE-576)297748874 |4 aut | |
| 700 | 1 | |a Debus, Jürgen |d 1964- |e VerfasserIn |0 (DE-588)1022671421 |0 (DE-627)717025780 |0 (DE-576)365774944 |4 aut | |
| 700 | 1 | |a Bendszus, Martin |e VerfasserIn |0 (DE-588)1032676426 |0 (DE-627)738634131 |0 (DE-576)175567697 |4 aut | |
| 700 | 1 | |a Platten, Michael |d 1971- |e VerfasserIn |0 (DE-588)121627780 |0 (DE-627)081431848 |0 (DE-576)261969811 |4 aut | |
| 700 | 1 | |a Wick, Wolfgang |d 1970- |e VerfasserIn |0 (DE-588)120297736 |0 (DE-627)080586929 |0 (DE-576)186221320 |4 aut | |
| 700 | 1 | |a Lemke, Dieter |d 1976- |e VerfasserIn |0 (DE-588)130145920 |0 (DE-627)492505861 |0 (DE-576)298024373 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular cancer research |d Philadelphia, Pa. : AACR, 2002 |g 16(2018), 5, Seite 767-776 |h Online-Ressource |w (DE-627)359783538 |w (DE-600)2097884-4 |w (DE-576)105430749 |x 1557-3125 |7 nnas |a Inhibition of CD95/CD95L (FAS/FASLG) signaling with APG101 prevents invasion and enhances radiation therapy for glioblastoma |
| 773 | 1 | 8 | |g volume:16 |g year:2018 |g number:5 |g pages:767-776 |g extent:10 |a Inhibition of CD95/CD95L (FAS/FASLG) signaling with APG101 prevents invasion and enhances radiation therapy for glioblastoma |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1541-7786.MCR-17-0563 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://mcr.aacrjournals.org/content/16/5/767 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190911 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 130145920 |a Lemke, Dieter |m 130145920:Lemke, Dieter |d 910000 |d 911100 |e 910000PL130145920 |e 911100PL130145920 |k 0/910000/ |k 1/910000/911100/ |p 24 |y j | ||
| 998 | |g 120297736 |a Wick, Wolfgang |m 120297736:Wick, Wolfgang |d 910000 |d 911100 |e 910000PW120297736 |e 911100PW120297736 |k 0/910000/ |k 1/910000/911100/ |p 23 | ||
| 998 | |g 121627780 |a Platten, Michael |m 121627780:Platten, Michael |d 60000 |d 62700 |e 60000PP121627780 |e 62700PP121627780 |k 0/60000/ |k 1/60000/62700/ |p 21 | ||
| 998 | |g 1032676426 |a Bendszus, Martin |m 1032676426:Bendszus, Martin |d 910000 |d 911100 |e 910000PB1032676426 |e 911100PB1032676426 |k 0/910000/ |k 1/910000/911100/ |p 19 | ||
| 998 | |g 1022671421 |a Debus, Jürgen |m 1022671421:Debus, Jürgen |d 910000 |d 911400 |e 910000PD1022671421 |e 911400PD1022671421 |k 0/910000/ |k 1/910000/911400/ |p 16 | ||
| 998 | |g 129612715 |a Abdollahi, Amir |m 129612715:Abdollahi, Amir |d 910000 |d 911400 |e 910000PA129612715 |e 911400PA129612715 |k 0/910000/ |k 1/910000/911400/ |p 15 | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 14 | ||
| 998 | |g 103034115X |a Deimling, Andreas von |m 103034115X:Deimling, Andreas von |d 910000 |d 912000 |e 910000PD103034115X |e 912000PD103034115X |k 0/910000/ |k 1/910000/912000/ |p 10 | ||
| 998 | |g 122759869 |a Wick, Antje |m 122759869:Wick, Antje |d 910000 |d 911100 |e 910000PW122759869 |e 911100PW122759869 |k 0/910000/ |k 1/910000/911100/ |p 6 | ||
| 998 | |g 1022852132 |a Sahm, Felix |m 1022852132:Sahm, Felix |d 910000 |d 912000 |e 910000PS1022852132 |e 912000PS1022852132 |k 0/910000/ |k 1/910000/912000/ |p 5 | ||
| 999 | |a KXP-PPN1676524452 |e 3514580839 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Jonas Blaes, Carina M. Thomé, Philipp-Niclas Pfenning, Petra Rübmann, Felix Sahm, Antje Wick, Theresa Bunse, Torsten Schmenger, Jaromir Sykora, Andreas von Deimling, Benedikt Wiestler, Christian Merz, Manfred Jugold, Uwe Haberkorn, Amir Abdollahi, Jürgen Debus, Christian Gieffers, Claudia Kunz, Martin Bendszus, Michael Kluge, Michael Platten, Harald Fricke, Wolfgang Wick, and Dieter Lemke"]},"title":[{"title":"Inhibition of CD95/CD95L (FAS/FASLG) signaling with APG101 prevents invasion and enhances radiation therapy for glioblastoma","title_sort":"Inhibition of CD95/CD95L (FAS/FASLG) signaling with APG101 prevents invasion and enhances radiation therapy for glioblastoma"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"display":"Blaes, Jonas","role":"aut","family":"Blaes","given":"Jonas"},{"display":"Sahm, Felix","role":"aut","family":"Sahm","given":"Felix"},{"given":"Antje","family":"Wick","display":"Wick, Antje","role":"aut"},{"given":"Andreas von","role":"aut","display":"Deimling, Andreas von","family":"Deimling"},{"given":"Uwe","display":"Haberkorn, Uwe","role":"aut","family":"Haberkorn"},{"given":"Amir","family":"Abdollahi","display":"Abdollahi, Amir","role":"aut"},{"given":"Jürgen","display":"Debus, Jürgen","role":"aut","family":"Debus"},{"display":"Bendszus, Martin","role":"aut","family":"Bendszus","given":"Martin"},{"given":"Michael","display":"Platten, Michael","role":"aut","family":"Platten"},{"family":"Wick","display":"Wick, Wolfgang","role":"aut","given":"Wolfgang"},{"given":"Dieter","display":"Lemke, Dieter","role":"aut","family":"Lemke"}],"id":{"doi":["10.1158/1541-7786.MCR-17-0563"],"eki":["1676524452"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"February 16, 2018"}],"language":["eng"],"note":["Gesehen am 11.09.2019"],"relHost":[{"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"corporate":[{"role":"isb","display":"American Association for Cancer Research"}],"physDesc":[{"extent":"Online-Ressource"}],"recId":"359783538","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"MCR"}],"pubHistory":["1.2002 -"],"language":["eng"],"disp":"Inhibition of CD95/CD95L (FAS/FASLG) signaling with APG101 prevents invasion and enhances radiation therapy for glioblastomaMolecular cancer research","title":[{"title":"Molecular cancer research","title_sort":"Molecular cancer research","subtitle":"MCR"}],"name":{"displayForm":["American Association for Cancer Research"]},"origin":[{"dateIssuedDisp":"2002-","dateIssuedKey":"2002","publisherPlace":"Philadelphia, Pa.","publisher":"AACR"}],"id":{"zdb":["2097884-4"],"eki":["359783538"],"issn":["1557-3125"]},"part":{"issue":"5","extent":"10","volume":"16","year":"2018","text":"16(2018), 5, Seite 767-776","pages":"767-776"}}],"physDesc":[{"extent":"10 S."}],"recId":"1676524452"} | ||
| SRT | |a BLAESJONASINHIBITION1620 | ||